Dupont Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Dupont Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-72,469	Closed	-$245K	–	1720
2021 Q1	$245K	Sell	72,469 -14,862	-17%	-$53.5K	0.01%	1222
2020 Q4	$245K	Sell	87,331 -6,518	-7%	-$19K	0.01%	1101
2020 Q3	$236K	Buy	93,849 +59,611	+174%	+$523K	0.01%	1065
2020 Q2	$465K	Sell	34,238 -3,057	-8%	-$31.6K	0.01%	814
2020 Q1	$283K	Buy	+37,295	New	+$290K	0.01%	882

Other funds holding AKBA

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Dupont Capital Management's AKBA Position: Q2 2021 in Review

Dupont Capital Management sold out of Akebia Therapeutics (AKBA) in Q2 2021, closing a stake of 72,469 shares — an estimated $245K sold.

Dupont Capital Management first reported a position in AKBA in Q1 2020 and held it in 5 quarters. The position peaked at $465K in Q2 2020. 139 funds tracked by Wall St. Rank hold AKBA as of Q2 2021.

Dupont Capital Management reported no remaining Akebia Therapeutics position as of Q2 2021 after selling out during the quarter.
Dupont Capital Management sold 72,469 Akebia Therapeutics shares in Q2 2021, an estimated $245K.
Dupont Capital Management first reported a position in Akebia Therapeutics in Q1 2020 and held it in 5 quarters.
Dupont Capital Management's Akebia Therapeutics position peaked at $465K in Q2 2020.
139 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2021.

Based on Dupont Capital Management's 13F filing for Q2 2021, filed 30 Jul 2021.